These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10550740)

  • 21. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
    Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
    J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule.
    Colás C; Monzón S; Venturini M; Lezaun A
    J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever.
    Ortolani C; Pastorello EA; Incorvaia C; Ispano M; Farioli L; Zara C; Pravettoni V; Zanussi C
    Allergy; 1994 Jan; 49(1):13-21. PubMed ID: 8198235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial.
    Ariano R; Kroon AM; Augeri G; Canonica GW; Passalacqua G
    Allergy; 1999 Apr; 54(4):313-9. PubMed ID: 10371089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
    Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
    Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L
    Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ; Antvelink JB; Luwema RA
    Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation.
    Passalacqua G; Albano M; Ruffoni S; Pronzato C; Riccio AM; Di Berardino L; Scordamaglia A; Canonica GW
    Am J Respir Crit Care Med; 1995 Aug; 152(2):461-6. PubMed ID: 7633693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.
    Bonvalet M; Moussu H; Wambre E; Ricarte C; Horiot S; Rimaniol AC; Kwok WW; Horak F; de Beaumont O; Baron-Bodo V; Moingeon P
    Clin Exp Allergy; 2012 Dec; 42(12):1745-55. PubMed ID: 23181790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy.
    Calderon MA; Birk AO; Andersen JS; Durham SR
    Allergy; 2007 Aug; 62(8):958-61. PubMed ID: 17620076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
    J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
    Mösges R; Ritter B; Kayoko G; Allekotte S
    Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rush immunotherapy with sublingual administration of grass allergen extract.
    Feliziani V; Marfisi RM; Parmiani S
    Allergol Immunopathol (Madr); 1993; 21(5):173-8. PubMed ID: 8160561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy.
    Ventura MT; Carretta A; Tummolo RA; Buquicchio R; Arsieni A; Murgia N
    Int J Immunopathol Pharmacol; 2009; 22(2):403-13. PubMed ID: 19505393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
    Wolthers OD; Høst A; Frederiksen B; Halken S
    Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
    Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
    J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.